[1]韩 娜,潘雅静,高丽娜,等.肠外营养支持联合HA280血液灌流治疗腹型过敏性紫癜临床研究*[J].陕西医学杂志,2020,49(6):708-712.[doi:DOI:10.3969/j.issn.10007377.2020.06.017]
　HAN Na,PAN Yajing,GAO Lina,et al.Clinical study of parenteral nutrition support combined with HA280 hemoperfusion in the treatment of children with abdominal allergic purpura[J].,2020,49(6):708-712.[doi:DOI:10.3969/j.issn.10007377.2020.06.017]
点击复制

肠外营养支持联合HA280血液灌流治疗腹型过敏性紫癜临床研究*
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
49
期数:
2020年6期
页码:
708-712
栏目:
临床研究
出版日期:
2020-06-05

文章信息/Info

Title:
Clinical study of parenteral nutrition support combined with HA280 hemoperfusion in the treatment of children with abdominal allergic purpura
作者:
韩 娜1; 潘雅静1; 高丽娜1; 乔柏林1; 刘勇志2
1.河北省唐山市丰润区人民医院儿科(唐山 064000); 2.石家庄肾病医院股份有限公司(石家庄 050061)
Author(s):
HAN Na; PAN Yajing; GAO Lina; et al.
Department of Pediatrics,Fengrun District People's Hospital,Tangshan City,Hebei Province(Tangshan 064000)
关键词:
肠外营养支持;  血液灌流;  腹型过敏性紫癜;  氧化应激反应
Keywords:
Parenteral nutrition support;  Hemoperfusion;  Abdominal allergic purpura;  Oxidative stress response
分类号:
R725.5
DOI:
DOI:10.3969/j.issn.10007377.2020.06.017
文献标志码:
A
摘要:
目的:探讨肠外营养支持联合HA280血液灌流治疗腹型过敏性紫癜患儿的临床效果。方法:选择腹型过敏性紫癜患儿96例,按照患儿的出生日期单日、双日分为对照组(n=48)和治疗组(n=48)。对照组患儿给予常规治疗,治疗组患儿在对照组治疗方法基础上进行血液灌流治疗,对比两组治疗期间糖皮质激素使用量、消化道症状持续时间、皮疹持续和住院时间。对比两组治疗前后的氧化应激指标变化情况。对比两组治疗前后的炎性因子变化情况。对比两组的临床治疗效果。对比两组治疗过程中的不良反应。结果:治疗组治疗期间糖皮质激素使用量、消化道症状持续时间、皮疹持续时间和住院时间均短于对照组(t=10.895、8.626、4.517、6.718,P<0.05)。经过治疗后,两组的血清丙二醛含量均降低,超氧化物歧化酶均增高(t=6.004,-3.292、11.405、-5.432,P<0.05),治疗后组间比较,治疗组丙二醛低于对照组,超氧化物歧化酶高于对照组(t=4.830、-2.277,P<0.05); 两组的TNF-α、IL-6均降低(t=11.750、26.782、13.553、30.166,P<0.05),组间比较,试验组的TNF-α、IL-6低于对照组(t=4.872、4.878,P<0.05),试验组治疗效果优于对照组(Z=1.799,P<0.05); 两组各项不良反应的发生率数据差异均不具有统计学意义(χ2=1.786、1.227、0.490、2.567、2.700,P>0.05)。结论:使用肠外营养支持联合HA280血液灌流治疗腹型过敏性紫癜患儿,可以有效控制患儿的症状,缩短住院时间,改善氧化应激与炎性反应指标,安全性良好。
Abstract:
Objective:To investigate the clinical effect of parenteral nutrition support combined with HA280 hemoperfusion in the treatment of children with abdominal allergic purpura.Methods:Ninety-six children with abdo minal allergic purpura were enrolled and divided into control group(n=48)and treatment group(n=48)according to the date of birth.The control group was treated with routine treatment,and the treatment group were treated with blood perfusion on the basis of the control group.The dosage of glucocorticoid during the treatment period,the duration of gastrointestinal symptoms,the duration of rash,and the length of hospital stay were compared between the two groups.The changes of oxidative stress indexes and inflammatory factors before and after treatment were compared between the two groups.The clinical effect and adverse reactions of the two groups were compared.Results:The dosage of glucocorticoid during the treatment period,the duration of gastrointestinal symptoms,the duration of rash,and the length of hospital stay in the treatment group were shorter than those in the control group(t=10.895,8.626,4.517,6.718,P<0.05).After treatment,the serum malondialdehyde content was decreased and the superoxide dismutase was increased in both groups(t=6.004,-3.292,11.405,-5.432,P<0.05).In the comparison between the two groups after treatment,the malondialdehyde in the treatment group was lower than that in the control group,and the superoxide dismutase was higher than that in the control group(t=4.830,-2.777,P<0.05).After treatment,TNF-α and IL-6 were decreased in both groups(t=11.750,26.782,13.553,30.166,P<0.05).In the comparison between the two groups after treatment,TNF-α and IL-6 in the treatment group were lower than those in the control group(t=4.872,4.878,P<0.05).The therapeutic effect of the treatment group was better than that of the control group(Z=1.799,P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(χ2=1.786,1.227,0.490,2.567,2.700,P>0.05).Conclusion:Parenteral nutrition support combined with HA280 hemoperfusion in the treatment of children with abdominal allergic purpura can effectively control the symptoms of children,shorten hospital stay,improve oxidative stress and inflammatory response indicators,and have good safety.

参考文献/References:

[1] 侯小芳,夏海龙.Th17细胞、IL-17和MMP-13在过敏性紫癜发病机制中的作用[J].中国实验血液学杂志,2018,(5):1502-1506.
[2] 罗 颖,黄艳艳,金 言,等.微小RNA-21对过敏性紫癜患儿B细胞白细胞介素10表达的影响[J].中华儿科杂志,2018,56(12):939-944.
[3] 任秀敏,贾秀红,张艳君,等.维生素E辅治过敏性紫癜的临床疗效及对炎症因子的影响[J].国际免疫学杂志,2018,41(1):37-40.
[4] 曾泽英,刘 烨,陈智荷,等.过敏性紫癜患儿发生并发症预测指标[J].实用医学杂志,2018,34(11):1847-1850.
[5] Zhu TF,Chu ZF,Li JH.Effect of tripterygium glycosides and Danshen injection on blood coagulation mechanism in children with allergic purpura nephritis[J].Zhongguo Zhong Yao Za Zhi,2016,41(11):2162-2167.
[6] Da DL,Zerbinati C,Strafella MS,et al.Henoch-schonlein purpura and drug and vaccine use in childhood:a case-control study[J].Ital J Pediatr,2016,42(1):60.
[7] 赵志新,高丛珊.中医辨证施护联合中药直肠滴入治疗腹型过敏性紫癜的效果评价[J].护理研究,2018,32(14):2304-2305.
[8] 郭 颖,尹仲衡,段行武,等.从五脏辨治过敏性紫癜的中医理论与临床应用探讨[J].环球中医药,2019,12(1):112-115.
[9] 李忠平,范青香,李晋霞,等.血液灌流救治急危重症有机磷中毒患者的疗效观察[J].中国中西医结合急救杂志,2019,26(1):117-119.
[10] 马国营,齐洪娜,肖青勉,等.大黄为主中药组方联合持续血液灌流对百草枯中毒患者的保护作用[J].实用医学杂志,2018,34(5):847-850.
[11] 张之南,沈 悌.血液病诊断及疗效标准[M].3 版.北京:科学出版社,2007:168.
[12] Kaneko M,Ikezumi Y,Yamada T,et al.Local leukocyte proliferation as a target for cyclophosphamide in the treatment of Henoch-Sehonlein purpura nephritis grade Ⅳ[J].Nephrology(C arlton),2016,21(1):68-71.
[13] 徐 锦,杨文萍,李 群,等.TGM2在过敏性紫癜肾损伤中的意义[J].南昌大学学报:医学版,2018,58(2):42-45.
[14] 中国医师协会儿科医师分会血液净化专家委员会.血液灌流治疗儿童重症过敏性紫癜的现状调查[J].中国小儿急救医学,2018,25(6):429-433.
[15] 李 婷,唐筱潇,阳海平,等.Tfh通过CD40/CD40L轴在介导儿童过敏性紫癜发病中的作用与机制初探[J].中华微生物学和免疫学杂志,2018,38(1):47-54.
[16] 兰连成,杨梅雄,单庆文,等.Th17在腹型过敏性紫癜胃肠黏膜损伤中的作用机制研究进展[J].广西医科大学学报,2019,36(1):148-151.
[17] 黄志宇,唐 清,云 翔,等.儿童腹型过敏性紫癜发生消化道出血的危险因素分析[J].广西医学,2018,40(9):1004-1008.
[18] 耿庆娜,付旭晖,王慧娟,等.甲强龙联合低分子肝素钙治疗儿童腹型过敏性紫癜的疗效观察[J].中国中西医结合皮肤性病学杂志,2018,17(5):410-412.
[19] 何春荣.甲基强的松龙联合丙种球蛋白治疗腹型过敏性紫癜疗效及对免疫功能的影响[J].海峡药学,2018,30(2):97-98.
[20] 谭惠丰,曹沛莲.不同血液净化方式对终末期肾病炎症因子及相关指标的影响[J].医学临床研究,2018,35(5):909-911.
[21] 马 舰,赵 智,杜 昌,等.早期连续性肾脏替代治疗联合血液灌流对急性重症胰腺炎患者肺功能及预后的影响[J].中国基层医药,2018,25(7):890-894.

备注/Memo

备注/Memo:
*河北省中医药管理局科研项目(2018272)
更新日期/Last Update: 2020-07-28